Aurobindo Pharma
Last updated Jul 12, 2026
Evidence Sources
3
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
8
Clinical Programs
0
Confidence Coverage
67%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Psychiatry
- Antipsychotic
- Neurology
- Antiepileptic
- Diabetes
Highest priority development: Unique Pharmaceutical Laboratories (A Div.
Regulatory precedent
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Aurobindo Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 67%
Active Signals
25
Investigate Priority
0
Opportunity Score
2939
Buyer Quality
3 · Low Priority
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJul 12, 2026Score 119FDA Approval Status Update for Deutetrabenazine by Aurobindo Pharma
Neurology · Movement Disorders
- MonitorJul 20, 2026Score 118Aurobindo Pharma's Olanzapine ANDA203708 Receives AP Status from FDA
Psychiatry · Antipsychotic
- MonitorJul 20, 2026Score 118Aurobindo Pharma's Lacosamide ANDA209224 Receives AP Status from FDA
Neurology · Antiepileptic
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- Unique Pharmaceutical Laboratories (A Div.Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Guidance Recap Podcast | Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology ConsiderationsModerate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Internet Pharmacy Warning LettersModerate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Capital Markets
SEC filings, IPO activity, and capital markets events from the Business Intelligence Layer.
No capital markets intelligence is available yet.
Financing History
Venture funding, follow-on offerings, PIPE financings, and debt financing.
No financing history is available yet.
Licensing & Partnerships
Licensing agreements, strategic partnerships, and distribution deals.
No licensing or partnership activity is available yet.
M&A Activity
Acquisitions, mergers, and divestitures.
No M&A activity is available yet.
Investor Activity
Earnings releases, investor presentations, and conference appearances.
No investor activity is available yet.
Executive Changes
CEO appointments, board changes, and leadership restructuring.
No executive changes are available yet.
Business Timeline
Chronological business intelligence events across financing, licensing, M&A, and commercial strategy.
No business timeline events are available yet.
Strategic Signals
Higher-order strategic intelligence fused from regulatory, scientific, business, and competitive events. Signals answer what it means — not just what happened.
Strategic signals will appear once sufficient event convergence is detected.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Aurobindo Pharma right now?
- Which regulatory precedents should Aurobindo Pharma monitor in Psychiatry and Antipsychotic?
- Which pipeline programs should Aurobindo Pharma prioritize for competitive review?
- What signals require immediate investigation for Aurobindo Pharma?
- Summarize the strategic implications of recent developments for Aurobindo Pharma.
- Where is the greatest uncertainty in Aurobindo Pharma's competitive positioning?